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γ-Tocotrienol (γT3) is an isomer of unsaturated vitamin E 
known to exert potent anti-inflammatory functions in vari-
ous cell types including macrophages, adipocytes, and sev-
eral cancerous cells (1). There is emerging evidence suggest-
ing that γT3 promotes insulin sensitivity, attenuates adipose 
inflammation, and decreases hepatosteatosis (2–5). The inhi-
bition of nuclear factor κB (NFΚB) signaling has been impli-
cated in the underlying mechanism by which γT3 regulates 
cellular processes from cell proliferation to insulin sensiti-
zation (5–7). However, the fundamental molecular mecha-
nism whereby γT3 modulates inflammation in diverse cell 
types and mitigates the accompanying pathophysiological 
sequelae is unknown. 
Inflammasomes are multiprotein cytosolic receptors that 
detect damage signals triggered by invasion of pathogens or 
by metabolic stresses leading to production of type 1 inter-
ferons and proinflammatory cytokines. Excessive activation 
of inflammasomes is frequently associated with the prev-
alence of various chronic inflammatory diseases including 
multiple sclerosis, Alzheimer’s disease, atherosclerosis, age-
related macular degeneration, and type 1 and 2 diabetes 
(8). Notably, a critical role of the NOD-like receptor protein 
3 (NLRP3) inflammasome has been established in the pro-
gression of insulin resistance to type 2 diabetes (9–11). The 
assembly of inflammasomes is initiated by scaffolding pro-
teins, either NLR (NOD-like receptor proteins) or AIM2 (ab-
sent in melanoma 2). It subsequently recruits adaptor pro-
tein ASC (apoptosis-associated speck-like protein containing 
a caspase recruitment domain) and pro-caspase-1. Upon as-
sembly of the inflammasome, caspase-1 becomes active and 
in turn activates proinflammatory cytokines pro-interleukin 
(IL)-1β and pro-IL-18 through proteolytic cleavage, resulting 
in the secretion of IL-1β and IL-18 and cell pyroptosis (re-
viewed in Ref. 12). Activation of the NLRP3 inflammasome 
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Abstract 
The Nod-like receptor 3 (NLRP3) inflammasome is an intracellular sensor that sets off the innate immune system in response to mi-
crobial-derived and endogenous metabolic danger signals. We previously reported that γ-tocotrienol (γT3) attenuated adipose tissue 
inflammation and insulin resistance in diet-induced obesity, but the underlying mechanism remained elusive. Here, we investigated 
the effects of γT3 on NLRP3 inflammasome activation and attendant consequences on type 2 diabetes. γT3 repressed inflammasome 
activation, caspase-1 cleavage, and interleukin (IL) 1β secretion in murine macrophages, implicating the inhibition of NLRP3 inflam-
masome in the anti-inflammatory and antipyroptotic properties of γT3. Furthermore, supplementation of leptin-receptor KO mice 
with γT3 attenuated immune cell infiltration into adipose tissue, decreased circulating IL-18 levels, preserved pancreatic β-cells, and 
improved insulin sensitivity. Mechanistically, γT3 regulated the NLRP3 inflammasome via a two-pronged mechanism: 1) the induction 
of A20/TNF-α interacting protein 3 leading to the inhibition of the TNF receptor-associated factor 6/nuclear factor κB pathway and 
2) the activation of AMP-activated protein kinase/autophagy axis leading to the attenuation of caspase-1 cleavage. Collectively, we 
demonstrated, for the first time, that γT3 inhibits the NLRP3 inflammasome thereby delaying the progression of type 2 diabetes. This 
study also provides an insight into the novel therapeutic values of γT3 for treating NLRP3 inflammasome-associated chronic diseases.
Keywords:  inflammation, obesity, vitamin E, insulin signaling, diet and dietary lipids, NOD-like receptor protein 3, A20, caspase 1   
Abbreviations: AMPK, AMP-activated protein kinase; BMDM, bone marrow-derived macrophage; BW, body weight; CM, conditioned medium; 
CQ, chloroquine; DAMP, damage-associated molecular pattern; γT3, γ-tocotrienol; GLuc, Gaussia luciferase; GTT, glucose tolerance test; H&E, he-
matoxylin and eosin; iGLuc, pro-interleukin-1β-Gaussia luciferase; iJ774, J774 macrophage stably expressing iGLuc; IL, interleukin; ITT, insulin tol-
erance test; NFκB, nuclear factor κB; Ng, nigericin; NLRP3, NOD-like receptor protein 3; PA; palmitate; PAMP, pathogen-associated molecular pat-
tern; qPCR, quantitative PCR; SV, stromal vascular; TNFAIP3, TNF-α interacting protein 3 (same as A20); TRAF6, TNF receptor-associated factor 6; 
WAT, white adipose tissue.
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is regulated by two discrete signaling cues: the priming and 
assembly of the inflammasome. The priming of NLRP3 in-
flammasome consists of the transcription of inflammasome 
components and requires NFΚB-mediated transcription of 
pro-Il-1β, pro-Il-18, and Nlrp3 (13). Subsequently, the inflam-
masome assembles in response to the engagement of pat-
tern recognition receptors by pathogen-associated molecu-
lar pattern (PAMP) or damage-associated molecular pattern 
(DAMP) endogenous signals (sterile inflammation); the lat-
ter include FFA, free cholesterol, uric acid, and ATP. One of 
the key mechanisms by which inflammasome assembly can 
be repressed is autophagic degradation of these deleterious 
molecular factors (reviewed in Ref. 14). 
Our previous work as well as others has shown that γT3 
can block NFΚB activation (5–7) and stimulate AMPacti-
vated protein kinase (AMPK) and autophagy in a variety of 
cell types (15–18). In the present study, we ask whether γT3 
represses the NLRP3 inflammasome and associated inflam-
matory processes in type 2 diabetes by modulating NFΚB, 
AMPK, and autophagy signaling pathways. Using murine 
macrophages and leptin receptor knockout (db/db) mice, we 
clearly show that γT3 blocks NLRP3 inflammasome activation 
and ameliorates type 2 diabetes. 
Research Design and Methods
Chemicals and reagents 
γT3 (with 90% purity) was kindly provided by Carotech. γT3 was 
prepared as previously described (18). Compound C was pur-
chased from Calbiochem. All other chemicals and reagents were 
purchased from Sigma Chemical Co., unless otherwise stated. 
Animals 
All animal experimental procedures were approved by the Insti-
tutional Animal Care and Use Committee at the University of Ne-
braska-Lincoln. Male BKS.Cg-Dock7m+/+Leprdb/J mice (referred to 
as db/db mice) were obtained from Jackson Laboratory. Animals 
were housed in a specific pathogen-free facility and given free 
access to food and water. Mice (6 weeks old) were fed a standard 
AIN93G diet (control) or the AIN93G containing 0.1% (w/w) γT3 
for 8 weeks. Mice were given fresh rations daily. Food and wa-
ter consumption were measured every day for 3 days during the 
last week of feeding before euthanasia. Individual body weights 
were measured weekly. 
Preparation of bone marrow-derived macrophages and 
stimulation for inflammasome 
Primary bone marrow cells were isolated from the femurs of 
6- to 10-week-old C57BL/6 mice and stimulated to differenti-
ate for 7–10 days in L-cell conditioned medium (CM) as we de-
scribed previously (5). The resulting differentiated bone mar-
row-derived macrophages (BMDMs) were pretreated with γT3 
or vehicle (DMSO) for 24 h, then primed with lipopolysaccha-
ride (LPS) (100 ng/ml) for 1 h, and stimulated either with nige-
ricin (Ng; 6.5 μM, a K+/H+ ionophore) for 1 h or palmitate (PA; 
400 μM complexed with BSA) for 12 h. 
Pro-IL-1β - Gaussia luciferase reporter assay 
The J774 macrophages stably expressing pro-IL-1β-Gaussia lucif-
erase (iGLuc) fusion construct (Figure 1A) were a generous gift 
from Dr. Hornung (hereafter referred to as iJ774 macrophages) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(19). iJ774 macrophages were cultured in DMEM supplemented 
with l-glutamine, sodium pyruvate, and 10% (v/v) FBS (Gibco). 
To determine Gaussia luciferase (GLuc) activity, the BioLux GLuc 
assay kit (NEB Inc.) was used and read with a Synergy H1 mul-
timode reader (BioTek). The cleavage product of the pro-IL-1β-
iGLuc fusion protein was detected in the media by Western blot 
analysis using anti-GLuc antibody (NEB Inc.). 
Glucose and insulin tolerance tests 
A glucose tolerance test (GTT) was performed on fasted (over-
night) db/db mice by intraperitoneal injection of 10% d-glucose 
solution [0.5 g/kg body weight (BW)]. Blood glucose levels (mg/
dl) were measured at 0, 15, 30, 60, and 120 min after injec-
tion using a glucometer (Bayer, Contuor). Plasma insulin levels 
at basal and 30 min after glucose intraperitoneal injection were 
determined by ELISA (Crystal Chem). For insulin tolerance test 
(ITT), fasted (4 h) db/db mice were administered 1 U/kg BW of 
insulin (Novolin R); blood glucose levels were measured at 0, 15, 
30, and 60 min after injection. 
Quantitative real-time PCR 
Gene expression analysis was performed as described previously 
(18). Relative gene expression was determined based on the 2–
ΔΔCT method with normalization of the raw data to either 36b4 
or Gapdh (see primer sequences in supplementary Table 1). For 
PCR microarray analysis, RT2 profiler PCR array for mouse inflam-
masome (PAMM-097ZD) was used according to the manufactur-
er’s instruction (Qiagen). For each treatment, equal amounts of 
total mRNA obtained from four mice were pooled. The results 
were analyzed using software provided by Qiagen.  
Figure 1. γT3 suppressed NLRP3 inflammasome procaspase reporter 
activity in iJ774 macrophages. iJ774 macrophages were preincubated 
with γT3 (0–5 μM) for 24 h before LPS priming (100 ng/ml for 1 h) and 
subsequent Ng stimulation. A. Structure of the iGLuc (NLRP3 inflamma-
some and caspase activity reporter constructs). B. Relative GLuc activity 
was quantified by luminometer. C. IL-1β secretion (in medium) quanti-
fied by ELISA. Results in B and C are shown as the mean ± SEM (n = 6). 
Values not sharing a common letter differ significantly (P < 0.05) by one-
way ANOVA. D. Cleavage of caspase-1 in cell extract and supernatant. 
Results in D are representative of triplicate samples. 
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Immunoblotting, immunoprecipitation, and ELISA 
Total cell and tissue extract preparation and Western blot proce-
dures were conducted as we described previously (5). The anti-
bodies recognizing phospho(p)-p38 (Thr180/182), TNF-α inter-
acting protein 3 (A20/TNFAIP3), ATG5, p-IKKα/β (Ser176/180), 
K63-linkage polyubiquitin, K48-linkage polyubiquitin, p-p44/42-
ERK1/2 (Thr202/204), total (t)-ERK, p-AMPKα (Thr 172), t-AMPK, 
β-actin, LC3, p62, Beclin-1, IκBα, and p-IκBα (Ser32/36) were 
purchased from Cell Signaling Technology. Antibodies against 
NLRP3, TNF receptor-associated factor 6 (TRAF6), and caspase-1 
(p20) were purchased from R&D Systems, Santa Cruz Biotechnol-
ogy, and AdipoGen, respectively. For the immunoprecipitation of 
ubiquitinated-TRAF6, protein A/G magnetic beads (Pierce) were 
used according to the manufacturer’s instruction. Plasma levels 
of adiponectin, IL-18, and IL-1β were quantified by using com-
mercial ELISA kits from R&D Systems. 
Isolation of stromal vascular cells and flow cytometric 
analysis 
Epididymal fat pads were collected at the time of necropsy and 
used for stromal vascular (SV) cell isolation by following the pro-
tocol of Orr et al. (20). For cell surface staining, cells were stained 
for 30 min at room temperature in FCS-PBS buffer (1%) with the 
following antibodies: FITC-CD4, PE-CD8, and APC/Cy7 CD45 and 
relative isotypes (BioLegend). SV cells were gated using forward 
and side scatter characteristics for lymphocytes on the basis of at 
least 10,000 events using a FACSCalibur™ flow cytometer (BD Bio-
sciences). Data were analyzed using FlowJo software (Treestar). 
Hematoxylin and eosin staining, islet size determination, 
and insulin staining 
Paraffin-embedded epididymal adipose tissues from mice were 
sectioned (10 μm) for hematoxylin and eosin (H&E) staining. Par-
affin-embedded pancreases were serially sectioned (5 μm) at 50 
μm intervals and used for H&E staining and insulin immunos-
taining. For determination of average islet size, ~150–200 islets 
were counted per mouse pancreas from the six serial sections of 
H and E-stained paraffin block (using Image J software). For insu-
lin staining, pancreas sections were incubated with a primary in-
sulin antibody (dilution 1:50, Dako), followed by incubation with 
EnVision-AP™ (Dako) and visualized using a SIGMA-FAST™ Fast 
Red system with hematoxylin counterstaining. 
siRNA transfection 
siRNAs (On-Target smart pool) targeting mouse A20 (Tnfaip3) or 
nontargeting siRNA control were transfected into iJ774 macro-
phages at a final concentration of 100 nM using Dharma-FECT4 
transfection reagent (GE Dharmacon). Forty-eight hours after 
transfection, cells were washed and stimulated as indicated in 
the figure legends. 
Statistics 
The two-tailed Student’s t-test was used for statistical analyses 
of two-group comparisons. Multigroup comparisons were per-
formed by a one-way ANOVA followed by Tukey’s multiple com-
parison test. All statistical analyses were performed using Graph-
Pad Prism 6 (version 6.02). 
Results
γT3 Inhibited NLRP3 inflammasome activation in 
macrophages 
To test whether γT3 suppresses NRLP3-inflammasome ac-
tivation, we first performed the iGLuc reporter assay for in-
flammasome and protease activity (Figure 1A) in iJ774 mac-
rophages. The γT3 (0–5 μM) dose-dependently decreased 
Gaussia luminescence upon Ng stimulation of LPS-primed 
iJ774 macrophages (Figure 1B). Similarly, IL-1β secretion in 
the medium decreased gradually with increasing dose of γT3 
(Figure 1C). In addition, we observed a stepwise decrease of 
cleaved caspase-1, a surrogate marker for caspase-1 activa-
tion, in both cell extracts and supernatants upon treatment 
with graded dose of γT3 (Figure 1D). We confirmed these re-
sults in primary BMDMs where pretreatment with 1 μM γT3 
repressed the secretion of IL-1β and IL-18 in LPS-primed Ng-
stimulated cells (Figure 2A). The mRNA levels of Il-1β, Il-18, 
and Nlrp3 were also markedly decreased by γT3 (Figure 2B), 
suggesting that γT3 suppresses the priming of NLRP3 in-
flammasome. Additionally, the abundance of NLRP3 protein 
and caspase-1 cleavage were decreased, whereas LC3II and 
p-AMPKα (Thr172) were increased by γT3 (Figure 2C). To de-
termine whether γT3 is able to suppress DAMP-triggered in-
flammasome activation, LPS-primed BMDMs were stimulated 
with 400 μM of PA. γT3 pretreatment (1 μM) remarkably re-
duced: 1) the secretion of IL-1β and IL-18 in the medium (Fig-
ure 2D); 2) the mRNA levels of Il-1β, Il-18, and Nlrp3 (Figure 
2E); and 3) the protein abundance of NLRP3 and cleaved cas-
pase-1 (Figure 2F). γT3 concomitantly induced LC3II accumu-
lation and AMPK phosphorylation (Figure 2F) implying that 
the AMP kinase/autophagy axis was stimulated. 
γT3 ameliorated the progression of type 2 diabetes in 
db/db mice 
To determine the effectiveness of γT3 supplementation in 
preventing the progression of type 2 diabetes, db/db mice 
were fed either an AIN93G diet devoid of γT3 (control) or an 
AIN93 diet containing 0.1% γT3 (1 g/kg diet) for 8 weeks. 
Feeding γT3 to db/db mice was associated with the improve-
ment of diabetic hyperphagia (Figure 3A) and diabetic thirst 
(polydipsia) (Figure 3B), and a slight but significant increase 
in body weight (Figure 3C). Importantly, results show a sig-
nificant decrease in fasting glucose levels (Figure 3D), but an 
increase of adiponectin levels (Figure 3E). γT3 also improved 
glucose disposal during the GTT (Figure 3F). There was no 
significant change in fasting insulin levels between the two 
groups. However, 30 min within the GTT, plasma insulin failed 
to rise in control mice, whereas in γT3-fed mice plasma insu-
lin levels were increased ~2-fold (Figure 3G). During the ITT, 
the insulin injection (1 U/kg BW) markedly improved glucose 
clearance to the same extent in both groups of mice (Figure 
3H). H&E staining of pancreatic islet cells revealed that the 
average islet size was significantly larger in γT3-fed mice than 
in controls (Figure 3I), and the islet size distribution shifted 
toward larger sizes in γT3-fed mice (Figure 3J). Moreover, the 
percentage of insulin- positive area per islet was significantly 
higher in γT3- fed mice than controls (5.9% vs. 2.4%; Figure 
3K). The immunostaining of the islets also showed that islet 
integrity was better preserved in γT3-fed mice with a low de-
gree of immune cell infiltration (Figure 3L). Collectively, these 
data indicate that γT3 attenuates the loss of pancreatic β-cells 
and delays the progression of type 2 diabetes in db/db mice. 
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γT3 suppressed NLRP3 inflammasome activation in 
peritoneal macrophages of db/db mice 
We asked whether the observed improvement of type 2 dia-
betes sequelae by γT3 was due to the suppression of NLRP3 
inflammasome activation and associated inflammatory pro-
cesses. We found that plasma IL-18 was decreased by ~2-fold 
in γT3-fed versus control mice (Figure 4A), whereas IL-1β 
levels were below detection limit in both groups. Next, we 
isolated the peritoneal macrophages from db/db mice fed 
the experimental diets for 8 weeks to carry out further anal-
ysis. Consistent with the results in Figure 1 , the mRNA levels 
of NFΚB target genes, which included Il-6, Tnfα , Il-1β , Il-18 
, and Nlrp3 , were significantly downregulated in the mac-
rophages of γT3-fed mice (Figure 4B). There was a ~40-fold 
increase in A20 transcript levels, a negative feedback regu-
lator of NFκB (Figure 4B). The inflammasome 84-gene array 
revealed that no gene was significantly upregulated by γT3 
supplementation. However, six genes (i.e., Il-12b, Nlrp3, Nfk-
bib, Nlrc5, NLrp4b, and Nlrp12) were differentially downreg-
ulated >2-fold in the macrophages of γT3-fed mice (Figure 
4C ; also see supplementary Table 2). Western blot analy-
ses showed that the macrophages of γT3-fed mice had less 
phosphorylated MAP kinase (p-ERK and p38), more IκBα and 
A20/TNFAIP3, and less NLRP3 and cleaved caspase-1 (Fig-
ure 4D). 
We also investigated the role of γT3 in autophagy in peri-
toneal macrophages of db/db mice. p-AMPKα (Thr 172) as 
well as markers of autophagic activation, including Beclin-1, 
autophagy protein 5 (ATG5), and LC3II, were markedly in-
creased by γT3, whereas p62 was decreased by γT3 (Fig-
ure 4E). Because p62 is degraded in autolysosome, p62 lev-
els are inversely correlated with autophagic flux. To confirm 
that the autophagic flux was stimulated by γT3, BMDMs were 
treated with chloroquine (CQ), a lysosomal degradation in-
Figure 2. γT3 inhibited NLRP3 infl ammasome in BMDMs. BMDMs were preincubated with vehicle (DMSO) or γT3 (1 μM). Inflammasome activation 
was triggered by either Ng (A–C) or PA (D, E) in LPS-primed BMDMs. IL-1β and IL-18 secreted in culture medium was measured by ELISA (A, D). The 
mRNA levels of Il-1β, Il-18, and Nlrp3 were analyzed by quantitative PCR (qPCR) (B, E). The protein levels of NLRP3, caspase-1, LC3, p-AMPKα (Thr172), 
and β-actin in cell lysates determined by Western blot (C, F). All data are shown as mean ± SEM in A, B, D, and E (n = 6 per group). Values not shar-
ing a common letter differ significantly (P < 0.05) by one-way ANOVA. Results in C and F are representative of triplicate samples.  
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hibitor. γT3 (but not control) led to LC3II accumulation and 
p62 degradation in CQ-treated BMDMs (Figure 4F) implying 
that γT3 coregulates autophagosome formation and inflam-
masome activation. Taken together, these data revealed that 
γT3 decreased NLRP3 inflammasome activation in macro-
phages of db/db mice. 
γT3 decreased immune cell infiltration into white adi-
pose tissue and preserved insulin sensitivity 
The impact of γT3-mediated suppression of NLRP3 inflam-
masome activation on adipose tissue inflammation was fur-
ther investigated in epididymal white adipose tissue (WAT) of 
db/db mice. H&E staining revealed that γT3 supplementation 
significantly reduced immune cell infiltration into WAT (Fig-
ure 5A). Flow cytometric analysis of the SV fractions showed 
that total macrophage infiltration (F4/80+) was decreased by 
~30% in γT3-fed versus control mice (12.3% vs. 8.3%; Fig-
ure 5B). In addition, Cd11c gene expression was substan-
tially decreased in the WAT of γT3-fed mice (Figure 5C). In 
accordance with the anti-inflammatory role of γT3 in perito-
neal macrophages (Figure 4C), feeding γT3 to db/db mice de-
creased the mRNA levels of Il-1β, Il-18, and Nlrp3 but raised 
those of A20 in WAT (Figure 5D). Flow cytometry data re-
vealed that the total leukocytes (CD45+) and cytotoxic T-cell 
populations (CD45+/CD8+) were significantly decreased in the 
WAT of γT3-fed mice compared with control WAT (Figure 5E). 
Next, we examined whether γT3 modulates NLRP3 infl am-
masome activation in WAT. Our results showed that γT3 sup-
plementation decreased NLRP3 expression, ERK phosphory-
lation, and caspase-1 cleavage, but increased protein levels 
of IκBα and A20 in epididymal WAT (Figure 5F). Furthermore, 
the WAT of γT3-fed mice exhibited higher AMPK phosphory-
lation (Thr172) and Beclin-1 and LC3II abundance, but lower 
abundance of p62 compared with control mice (Figure 5G), 
collectively suggesting activation of the AMPK/autophagy 
axis by γT3. 
To assess whether γT3 could preserve insulin sensitivity 
of adipocytes from the deleterious effects of IL-1β, primary 
mouse adipocytes differentiated from mesenchymal stem 
cells were first cultured with or without γT3 (1 μM). Then ad-
ipocyte cultures were exposed to the IL-1β-containing CM 
obtained from LPS/Ng-treated iJ774 (Figure 5H , left). The 
insulin-stimulated Akt phosphorylation was significantly re-
duced following exposure to the CM (Figure 5H , lane 5), un-
Figure 3.  γT3 ameliorated the progression of type 2 diabetes in db/db mice. Male db/db mice were fed with either an AIN93G control diet devoid of 
γT3 or an AIN93G diet containing 0.1% γT3 for 8 weeks (n = 12 mice per group). A. Food intake. B. Water intake. C. Body weight. D. Fasting glucose 
levels. E. Adiponectin levels (ELISA). F. GTT. G. Plasma insulin levels at 0 and 30 min after intraperitoneal glucose injection were quantified by ELISA. 
H. ITT. I. Average size of islets of Langerhans. J. Relative size distribution of the pancreatic islets. K. Percentage of insulin-positive area/pancreas area. 
L. Representative images of insulin-positive islet area after immunohistochemical staining of insulin (n = 5). All data are shown as mean ± SEM. * P 
< 0.05 ; ** P < 0.01 ; *** P < 0.001 by Student’s t-test.  
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less the adipocytes had received γT3 (Figure 5H , lane 6). Col-
lectively, these data demonstrate that γT3 reduced NFΚB and 
NLRP3 inflammasome activation in WAT resulting in attenu-
ation of adipose tissue inflammation and preservation of in-
sulin sensitivity. 
γT3 blocked NFΚB-mediated priming of the 
inflammasome 
NFκB activation is a critical step for the priming of the inflam-
masomes. Based on multiple observations that γT3 increased 
A20 expression (Figs. 4, 5), we hypothesized that γT3 inhib-
its NFΚB signaling pathway via activation of A20, an ubiqui-
tination-editing enzyme. We further hypothesized that A20 
activation hinders the ubiquitination of TRAF6. The forma-
tion of a polyubiquitin chain (K63-Ub) on TRAF6 is critical for 
TRAF6-mediated phosphorylation and activation of IKK. Fol-
lowing activation, IKK phosphorylates IκB, which undergoes 
proteosomal degradation thereby allowing NFκB to dimer-
ize into its active form (21). To test these hypotheses, BMDMs 
were pretreated with or without γT3 (1 μM) and then stimu-
lated with LPS, and mRNAs and proteins were collected over 
a 3 h time course. We found that Il-1β mRNA levels were in-
versely associated with those of A20 (Figure 6A). The ele-
vation of A20 protein abundance induced by γT3 coincided 
with: 1) the decrease of p-IκB kinase (IKK) α/β, p-ERK, and 
p-IκBα; 2) the reappearance of IκBα; and 3) the disappear-
ance of TRAF6, suggesting a negative feedback of A20 on 
TRAF6/IKK/NFκB signaling (Figure 6B). 
It has been shown that A20 can transfer TRAF6-bound Ub 
from residue K63 to K48 thereby causing the proteasomal 
degradation of TRAF6 (22). Thus, we performed immunopre-
cipitation to determine K63- versus K48-Ub status of TRAF6. 
As opposed to the study by Muroi and Tanamoto (22), inhi-
bition of proteasomal degradation by MG132 failed to rescue 
Figure 4. Feeding γT3 to db/db mice repressed the formation of NLRP3 inflammasomes in peritoneal macrophages. A. IL-18 levels (ELISA) in blood 
plasma collected from control and γT3-fed db/db mice (n = 6). B. The mRNA expression of Il-6, Tnfα, Il-1β, Il-18, A20, and Nlrp3 analyzed by qPCR 
in isolated peritoneal macrophages (n = 6). C. Microarray analysis of mouse inflammasome (84 genes) by qPCR. Pooled mRNA (n = 4 per group) 
was used for analysis. Target genes positioned outside the space defined by the broken lines are differentially expressed by at least 2-fold. Insert. 
Fold change of downregulated genes (open bar, control macrophages; closed bar, γT3-fed macrophages). D. Western blot analysis of p-ERK, t-ERK, 
p-p38, IκBα, A20, NLRP3, and cleaved caspase-1. E. Western blot analysis for p-AMPK and t-AMPK, and autophagyrelated protein expression of Be-
clin-1, Atg5, LC3, and p62 (see supplementary Figure 1 for quantification). F. BMDMs were stimulated for inflammasome formation by PA/LPS for 12 
h. CQ (10 μM, an autophagy inhibitor) was added 3 h before harvest. Protein levels of LC3I/II, p62, and β-actin were determined by Western blot (n 
= 3). Data in A and B are expressed as mean ± SEM. * P < 0.05 ; ** P < 0.01 ; *** P < 0.001. 
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Figure 5. γT3 supplementation regulated innate immune system and insulin sensitivity in WAT. Epididymal adipose tissues were isolated from the 
control and γT3-fed db/db mice. A. H and E staining. B. Flow cytometric determination of F4/80+ population from adipose SV fraction (representative 
flow cytogram of four mice per group). C. Cd11c gene expression (n = 6). D. mRNA expression Il-1β, Il-18, Nlrp3, and A20 (n = 6). Data are expressed 
as mean ± SEM. * P < 0.05 ; ** P < 0.01 ; *** P < 0.001. E. CD45+ and CD45+CD8+ T-cell fractions by flow cytometry (representative flow cytogram of 
four mice per group). F. Western blot analysis of NLRP3, IκBα , A20/TNFAIP3, cleaved caspase-1, and β-actin (loading control). G. Western blot analy-
sis of p-AMPK, t-AMPK, p62, Beclin-1, LC3, and β-actin. Each lane represents epididymal WAT from different animals (see supplementary Figure 2 for 
quantification). H. Inflammasome formation was stimulated by LPS/ Ng in iJ774 cells. Primary murine adipocytes were preincubated with γT3 before 
receiving the CM of LPS/Ng-treated iJ774 (left). Insulin (100 nM)-stimulated levels of p-Akt and t-Akt were determined by Western blot analysis (right). 
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the γT3-mediated decrease of TRAF6 or to increase K48-Ub 
of TRAF6 (Figure 6C). Similarly, γT3 also lowered K63-Ub of 
TRAF6 compared with controls (Figure 6D). Taken together, 
we posit that A20 induction by γT3 inhibited the ubiquiti-
nation of both the K48 and K63 residues of TRAF6 and pro-
moted TRAF6 nonproteasomal degradation, leading to early 
blockage of the NFΚB signaling pathway and repression of 
inflammasome priming. 
Inhibition of A20 and AMPK activation altered IL-1β se-
cretion and caspase-1 cleavage by γT3 
To determine whether AMPK mediates γT3’s inhibition of the 
inflammasome, we treated iJ774 macrophages with Com-
pound C (10 μM), a chemical inhibitor of AMPK. Results 
showed that Compound C partially reversed γT3-dependent 
decreases in IL-1β secretion (Figure 7A), caspase-1 cleav-
age (Figure 7B , top), and iGLuc activity (Figure 7B , bot-
tom). To ascertain the contribution of A20 induction by γT3 
in the lowering of IL-1β secretion and caspase-1 activation, 
A20 was knocked down in iJ774 macrophages using siRNAs 
. As expected, the silencing of A20 effectively decreased γT3-
mediated A20 induction but did not reverse γT3-mediated 
blockage of caspase-1 cleavage (Figure 7C). Although total 
IL-1β levels were significantly increased in siA20-transfected 
cells versus siControl cells, the extent to which γT3 attenu-
ated IL-1β secretion was not significantly different between 
siA20 and siControl cells (Δ of columns 1 and 2 vs. Δ of col-
umns 3 and 4; Figure 7D). Taken together, our results suggest 
that 1) AMPK mediates the blockage of caspase-1 cleavage 
afforded by γT3, 2) A20 downregulates NFκB-mediated pro-
duction of IL-1β , and 3) γT3 can inhibit IL-1β production in-
dependently of A20. 
Discussion
The activation of the NLRP3 inflammasome is positively asso-
ciated with the prevalence of type 2 diabetes. Consequently, 
targeting the inhibition of NLRP3 inflammasome is an attrac-
tive strategy against type 2 diabetes. In this study, we ad-
dressed the question of whether γT3, an unsaturated form 
of vitamin E, is effective in suppressing the NLRP3 inflamma-
some and mitigating the pathophysiological consequences of 
inflammation in a mouse model of type 2 diabetes. Our re-
sults showed that γT3 inhibits the NLRP3 inflammasome ac-
tivity by two-pronged mechanism: 1) the blockage of inflam-
masome priming and 2) the impediment of inflammasome 
activation. To our knowledge, this is the first study to charac-
terize the role of γT3 in inhibiting the NLRP3 inflammasome 
and show that, by acting through the inflammasome, γT3 di-
etary supplementation can improve insulin resistance in mice. 
Intense research is currently being devoted to the discov-
ery of chemical inhibitors of the NLRP3 inflammasome (23), 
blocking agents of the IL-1β signaling such as IL-1R (IL-1 re-
ceptor) antagonist (24), and neutralizing antibodies (25, 26). 
Although, there is growing evidence that nutrition is a criti-
cal modulator of the inflammasome, few attempts have been 
made to inhibit the NLRP3 inflammasome through diet. For 
instance, elevated levels of circulating FFAs were shown to 
activate the NLRP3 inflammasome and weaken insulin sen-
sitivity (27, 28). In contrast, ω-3 FA (29) and MUFAs (30) have 
Figure 6. γT3 blocked NFκB-mediated priming of the inflammasome in BMDMs. BMDMs were pretreated with vehicle (–) or γT3 (+) for 24 h. A, B. 
Cells were stimulated with LPS (100 ng/ml) at t = 0 h, then total RNA and cellular proteins were extracted at 0, 0.5, 1, and 3 h. A. Temporal changes 
in mRNA levels of Il-1β and A20 by qPCR. B. Temporal changes in protein abundance of A20, p-IKK, p-ERK, p-IκBα , IκBα , TRAF6, and β-actin by 
Western blot analysis. C. BMDMs were pretreated with proteasomal degradation inhibitor MG132 (50 μM) prior to LPS stimulation (1 h). Protein lev-
els of p-IΚBΑ, IκBα, TRAF6, and β-actin were determined by Western blot. Cell extracts were immunoprecipitated (IP) with K48 ubiquitination anti-
body (Ub-K48) then immunoblotted (IB) with antibodies against TRAF6. D. BMDMs were stimulated with LPS for 1 h. Cell extracts were immunopre-
cipitated (IP) with K63 ubiquitination antibody (Ub-K63) then immunoblotted (IB) with antibodies against TRAF6. Data are shown as mean ± SEM. 
** P < 0.01 ; *** P < 0.001. 
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been shown to curtail NLRP3 inflammasome activation. In 
this study, we report on the previously unrecognized func-
tion of γT3 [at physiologically relevant concentration (1)] as 
a potent negative regulator of the NLRP3 inflammasome. 
Our data clearly show that γT3 inhibited the NLRP3 inflam-
masome in three macrophage models [i.e., iJ774 macrocytic 
cells (Figure 1), primary BMDMs (Figure 2), and peritoneal 
macrophages freshly isolated from db/db mice (Figure 4)]. 
In addition, the suppression of NLPR3 inflammasomes by 
γT3 was evident upon stimulation of PAMP with Ng, and of 
DAMP with PA (Figure 2). We also found that γT3 altered 
the NLR-subset inflammasome, but not the AIM2-scaffold 
inflammasome, the adaptor protein ASC, or the other cas-
pases (Figure 4C), suggesting that γT3 has therapeutic po-
tential against metabolic diseases where the NLRP3 inflam-
masome is implicated, such as obesity, atherosclerosis, and 
type 2 diabetes (8). 
In the obese, the chronic stimulation of Toll-like receptor 4 
by FAs has been shown to activate the NLRP3 inflammasome 
of macrophages residing in the adipose tissue and provoke 
the massive influx of immune cells into WAT (27, 31). Here, 
we investigated the potential mitigating properties of dietary 
γT3 on the inflammatory and immunological consequences 
of obesity toward glycemia, insulinemia, and WAT remodel-
ing. To that end, we determined the composition of NLRP3 
inflammasomes, the extent of immune cell infiltration, and 
insulin sensitivity. We found that the lowering of NLRP3 in-
flammasome in the WAT of γT3-fed mice (Figure 5F) was as-
sociated with the lowering of cytotoxic CD8+ T cells and mac-
rophages in WAT (Figure 5A, B), and with the amelioration of 
insulin resistance (Figs. 3, 5H). 
The destruction of pancreatic β-cells and impairment of 
insulin production are hallmarks of late-stage type 2 diabe-
tes (32, 33). Because of a lack of specimens, we were unable 
to determine whether the protection of β cells afforded by 
γT3 (Figure 3I–L) was due to the blockage of infl ammasome 
formation within the islets or the insensitivity of β cells to the 
deleterious effects of IL-1β paracrine signaling. We are cur-
rently investigating whether γT3 inhibits the inflammasome 
of macrophages residing in islets or the inflammasome of β 
cells themselves, or both. 
Mechanistically, we had anticipated that γT3 would in-
hibit the priming of NLRP3 inflammasome based on γT3’s 
intrinsic ability to suppress NFκB (5). However, we did not 
anticipate that γT3 would augment A20 induction, an ubiq-
uitin-editing enzyme (34). Single nucleotide polymorphisms 
in the Tnfaip3/A20 are associated with increased suscepti-
bility to chronic inflammatory diseases (35, 36). Deletion of 
A20 has been shown to cause hypersensitivity to TNF-α due 
to the constitutive activation of NFκB, leading to premature 
death (37). In addition, an inverse correlation between dia-
betes incidence and A20 mRNA levels was found in patients 
with both type 1 and type 2 diabetes (38). In our study, mul-
tiple lines of evidence demonstrated that A20 is augmented 
by γT3 to mitigate the priming of the NLRP3 inflammasome 
(Figs. 4, 6, and 7). Recently, Wang et al. (39) have reported 
that γT3 causes A20 induction via regulation of sphingolipid 
metabolism. It is presently unknown whether alterations to 
sphingolipid metabolism by γT3 affected NLRP3 infl amma-
some activity in our study. Nonetheless, the work by Wang et 
al. corroborates our claim that γT3 protects against abnormal 
stimulation of the innate immune system in part through the 
upregulation of A20 and feedback inhibition of priming of the 
NLRP3 inflammasome. Indeed, A20 silencing with siRNA did 
not completely reverse γT3’s inhibition of IL-1β secretion (Fig-
ure 7C, D), suggesting that A20 activation is important but 
not sufficient, and full inhibition of NLRP3 inflammasome ne-
cessitates the coordinated involvement of additional factors. 
One of these factors may be autophagy because Matsuzawa 
et al. (40) reported that A20 activation and autophagy coop-
erate in T-cell survival. 
Autophagy regulates the fate of inflammasomes by en-
gulfing PAMP and DAMP signals (41, 42). We clearly demon-
strated that γT3 activates AMPK and autophagy (Figs. 2, 4, 
and 5). We further showed that the inhibition of AMPK with 
Compound C almost completely reversed γT3’s suppression 
of NLRP3 inflammasome and caspase-1 cleavage, indicating 
that AMPK activation is critically important in the mechanism 
of γT3 (Figure 7). Further research exploring the cross-talks 
between the A20 and AMPK/autophagy signaling pathways is 
needed to fully understand the precise mechanism by which 
γT3 suppresses NLRP3 inflammasome activation. 
Figure 7. AMPK and A20 contributed to γT3-mediated lowering of IL-1β 
secretion. iJ774 macrophages were treated with Compound C (10 μM) 
to inhibit AMPK (A–C) or transfected with either A20- targeting siRNA 
(siA20+) or nontargeting siRNA (siA20–) followed by LPS/PA stimulation 
for 12 h (C, D). A. Secreted IL-1β was measured by ELISA (n = 6). B. Rel-
ative GLuc activity of iGLuc (bottom) and caspase-1 cleavage (top). C. 
Western blot analysis of A20, cleaved caspase-1, and β-actin (represen-
tative of triplicate samples). D. Secreted IL-1β was measured by ELISA (n 
= 6). The dotted line indicates the basal IL-1β level of siCont cells primed 
with LPS/PA. All data are expressed as mean ± SEM. * P < 0.05 ; ** P < 
0.01 ; *** P < 0.001 ; ns, nonsignificant.  
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Most tocotrienol dietary supplements are provided as 
mixed formulations of α-, γ-, and δ-tocotrienols, with the ex-
ception of tocotrienol supplmentation isolated from annatto 
seeds, which contain >90% of δ-tocotrienol. The bioavailabil-
ity of γT3 has been shown to vary in humans depending on 
the tocotrienol composition of the dietary source, the target 
population, and the study design (reviewed in Ref. 43). Toco-
trienols circulate in blood bound to lipoproteins, in particu-
lar to HDL particles, suggesting that the plasma lipoprotein 
profile affects tocotrienol metabolism. Due to the low bind-
ing affinity of tocotrienols for the α-tocopherol transfer pro-
tein, the transfer of tocotrienols to HDL particles must occur 
via alternative, yet to be identified pathways (44, 45). The to-
cotrienol-rich fraction supplementations are considered safe. 
They obtained the GRAS (Generally Recognized as Safe) des-
ignation from the Food and Drug Administration. Based on a 
recent review by Podszun et al. (46), there is no clear evidence 
that high doses of vitamin E (>300 mg/day), either as tocotri-
enols or tocopherols, cause adverse effects in either animals 
or humans. However, we note that a meta-analysis of human 
studies with vitamin E raised some concerns with regard to 
high-dose vitamin E supplementation, which may have ad-
verse effects when consumed with certain drugs, such as as-
pirin (47). Despite some uncertainties regarding the metab-
olism of tocotrienols, multiple clinical studies support their 
beneficial effects against metabolic diseases (48). By show-
ing that γT3 inhibits the NLRP3 inflammasome and consid-
ering that the innate immune response plays a central role 
in metabolic disorders, our study may provide a possible ex-
planation for some of the clinical positive outcomes of toco-
trienol supplementation (8). 
In summary, the critical role of the NLRP3 inflammasome 
in the pathophysiology of insulin resistance was confirmed 
in human studies (49, 50). Hence, by revealing that γT3 sup-
plementation blunts NLRP3 inflammasome activity and de-
lays the progression of type 2 diabetes, our present work has 
clinical relevance. Although further investigations in human 
subjects are necessary to validate the therapeutic applicabil-
ity of our work, we herein present seminal evidence that γT3 
is an anti-inflammatory vitamin by inhibiting the NLRP3 in-
flammasome in macrophages. 
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Supplementary Table 1. Primer sequences for qPCR 
Gene Forward (5’3’) Reverse (5’3’) 
36B4 GGATCTGCTGCATCTGCTTG GGCGACCTGGAAGTCCAACT 
CD11c CTGGATAGCCTTTCTTCTGCT GCACACTGTGTCCGAACT 
F4/80 CTTTGGCTATGGGCTTCCAGTC   GCAAGGAGGACAGAGTTTATCGTG   
GAPDH CATGGCCTTCCGTGTTCCTA GCGGCACGTCAGATCCA 
IL-18 GACAGCCTGTGTTCGAGGAT TGGATCCATTTCCTCAAAGG 
IL-1β GTCACAAGAAACCATGGCACAT GCCCATCAGAGGCAAGGA 
IL-6 CTGCAAGAGACTTCCATCCAGTT AGGGAAGGCCGTGGTTGT 
NLRP3 ATGCTGCTTCGACATCTCCT AACCAATGCGAGATCCTGAC 
TNFα GGCTGCCCCGACTACGT ACTTTCTCCTGGTATGAGATAGCAAAT 
A20 AAACCAATGGTGATGGAAACTG GTTGTCCCATTCGTCATTCC 
 
Supplemental Table2. Fold changes of mouse inflammasome related genes by qPCR 
microarray in pooled peritoneal macrophages of db/db mice after 12 weeks of γT3 
supplementation.  
Abbreviation Description Fold  
Aim2 Absent in melanoma 2 1.1196 
Bcl2 B-cell leukemia/lymphoma 2 0.7285 
Bcl2l1 Bcl2-like 1 0.7049 
Birc2 Baculoviral IAP repeat-containing 2 0.7128 
Birc3 Baculoviral IAP repeat-containing 3 0.9341 
Card6 Caspase recruitment domain family, member 6 1.0997 
Casp1 Caspase 1 1.219 
Casp12 Caspase 12 1.0918 
Casp8 Caspase 8 1.1355 
Ccl12 Chemokine (C-C motif) ligand 12 1.4828 
Ccl5 Chemokine (C-C motif) ligand 5 0.8065 
Ccl7 Chemokine (C-C motif) ligand 7 1.2402 
Cd40lg CD40 ligand 0.7801 
Cflar CASP8 and FADD-like apoptosis regulator 0.7188 
Chuk Conserved helix-loop-helix ubiquitous kinase 1.1336 
Ciita Class II transactivator 0.6468 
Ctsb Cathepsin B 0.6855 
Cxcl1 Chemokine (C-X-C motif) ligand 1 0.5347 
Cxcl3 Chemokine (C-X-C motif) ligand 3 0.7117 
Fadd Fas (TNFRSF6)-associated via death domain 0.6265 
Hsp90aa1 Heat shock protein 90, alpha (cytosolic), class A member 1 1.0587 
Hsp90b1 Heat shock protein 90, beta (Grp94), member 1 0.6649 
Ifnb1 Interferon beta 1, fibroblast 1.0196 
Ifng Interferon gamma 1.3048 
Ikbkb Inhibitor of kappaB kinase beta 0.9313 
Ikbkg Inhibitor of kappaB kinase gamma 1.4305 
Il12a Interleukin 12A 0.857 
Il12b Interleukin 12B 0.4649 
Il18 Interleukin 18 0.556 
Il1b Interleukin 1 beta 0.5773 
Il33 Interleukin 33 0.7311 
Il6 Interleukin 6 0.9015 
Irak1 Interleukin-1 receptor-associated kinase 1 1.1393 
Irf1 Interferon regulatory factor 1 0.5369 
Irf3 Interferon regulatory factor 3 1.0506 
Irf4 Interferon regulatory factor 4 0.9299 
Map3k7 Mitogen-activated protein kinase kinase kinase 7 0.9728 
Mapk1 Mitogen-activated protein kinase 1 1.5487 
Mapk11 Mitogen-activated protein kinase 11 1.1737 
Mapk12 Mitogen-activated protein kinase 12 0.7196 
Mapk13 Mitogen-activated protein kinase 13 1.751 
Mapk3 Mitogen-activated protein kinase 3 0.9884 
Mapk8 Mitogen-activated protein kinase 8 0.5988 
Mapk9 Mitogen-activated protein kinase 9 0.8816 
Mefv Mediterranean fever 0.7729 
Myd88 Myeloid differentiation primary response gene 88 1.032 
Naip1 NLR family, apoptosis inhibitory protein 1 0.877 
Naip5 NLR family, apoptosis inhibitory protein 5 0.8364 
Nfkb1 
Nuclear factor of kappa light polypeptide gene enhancer in B-cells 
1, p105 0.9456 
Nfkbia 
Nuclear factor of kappa light polypeptide gene enhancer in B-cells 
inhibitor, alpha 0.9229 
Nfkbib 
Nuclear factor of kappa light polypeptide gene enhancer in B-cells 
inhibitor, beta 0.4697 
Nlrc4 NLR family, CARD domain containing 4 1.0828 
Nlrc5 NLR family, CARD domain containing 5 0.4488 
Nlrp12 NLR family, pyrin domain containing 12 0.265 
Nlrp1a NLR family, pyrin domain containing 1A 1.3147 
Nlrp3 NLR family, pyrin domain containing 3 0.3759 
Nlrp4b NLR family, pyrin domain containing 4B 0.3513 
Nlrp4e NLR family, pyrin domain containing 4E 1.8363 
Nlrp5 NLR family, pyrin domain containing 5 1.3688 
Nlrp6 NLR family, pyrin domain containing 6 1.0314 
Nlrp9b NLR family, pyrin domain containing 9B 0.9511 
Nlrx1 NLR family member X1 0.9174 
Nod1 Nucleotide-binding oligomerization domain containing 1 0.9508 
Nod2 Nucleotide-binding oligomerization domain containing 2 0.9979 
P2rx7 Purinergic receptor P2X, ligand-gated ion channel, 7 1.033 
Panx1 Pannexin 1 1.6384 
Pea15a Phosphoprotein enriched in astrocytes 15A 0.8337 
Pstpip1 Proline-serine-threonine phosphatase-interacting protein 1 1.1191 
Ptgs2 Prostaglandin-endoperoxide synthase 2 0.6537 
Pycard PYD and CARD domain containing 1.0224 
Rela V-rel reticuloendotheliosis viral oncogene homolog A (avian) 0.5653 
Ripk2 Receptor (TNFRSF)-interacting serine-threonine kinase 2 0.9019 
Stk30 Serine/threonine kinase 30 1.0472 
Sugt1 SGT1, suppressor of G2 allele of SKP1 (S. cerevisiae) 1.0874 
Tab1 TGF-beta activated kinase 1/MAP3K7 binding protein 1 0.6241 
Tab2 TGF-beta activated kinase 1/MAP3K7 binding protein 2 0.8919 
Tirap 
Toll-interleukin 1 receptor (TIR) domain-containing adaptor 
protein 1.1931 
Tnf Tumor necrosis factor 0.5095 
Tnfsf11* Tumor necrosis factor (ligand) superfamily, member 11 2.4853 
Tnfsf14 Tumor necrosis factor (ligand) superfamily, member 14 0.963 
Tnfsf4 Tumor necrosis factor (ligand) superfamily, member 4 0.6236 
Traf6 Tnf receptor-associated factor 6 0.8629 
Txnip Thioredoxin interacting protein 0.7104 
Xiap X-linked inhibitor of apoptosis 1.1982 
Actb Actin, beta 0.928 
B2m Beta-2 microglobulin 0.8583 
Gapdh Glyceraldehyde-3-phosphate dehydrogenase 1.0041 
Gusb Glucuronidase, beta 0.7756 
Hsp90ab1 Heat shock protein 90 alpha (cytosolic), class B member 1 0.9962 
*Ct cycle >30 
  
 Supplemental Fig1. Band densitometry of Fig 4D (A) and Fig 4E (B) was quantified with Image 
J software and normalized to β-actin with the exception of p-ERK that was normalized to t-ERK, 
LC3II that was normalized to LC3I, and p-AMPK that was normalized to t-AMPK. Open bars 
correspond to peritoneal macrophages isolated from mice fed control diet. Closed bars correspond 
to peritoneal macrophages isolated from mice fed 0.1% γT3. *P<0.05, **P<0.001 by Student’s t-
test.  
 
  
 Supplemental Fig2. Band densitometry of Fig 5F (A) and Fig 5G (B) was determined with 
Image J software and normalized to β-actin with the exception of p-ERK that was normalized to 
t-ERK, LC3II that was normalized to LC3I, and p-AMPK that was normalized to t-AMPK. Open 
bars correspond to WAT of mice fed control diet. Closed bars correspond to WAT of mice fed 
0.1% γT3. *P<0.05, **P<0.001 by Student t-test. 
 
